UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers
Deal builds upon UCB’s position as a leader in immunology innovation and expands capabilities in next generation biologics with potential for immune reset Candid’s lead asset, cizutamig, a bispecific antibody directed to B-cell maturation antigen (BCMA) on plasma cells and CD3 on T-cells, is currently in multiple phase 1 clinical studies across various autoimmune diseases […]